HighVista Strategies LLC Grows Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

HighVista Strategies LLC grew its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 38.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,661 shares of the company's stock after acquiring an additional 12,348 shares during the period. Vaxcyte comprises about 1.8% of HighVista Strategies LLC's portfolio, making the stock its 3rd largest holding. HighVista Strategies LLC's holdings in Vaxcyte were worth $5,103,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of PCVX. Riverview Trust Co bought a new position in Vaxcyte in the 3rd quarter valued at about $27,000. Blue Trust Inc. increased its stake in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock worth $42,000 after purchasing an additional 93 shares during the period. Fifth Third Bancorp bought a new stake in Vaxcyte in the 2nd quarter valued at $35,000. J.Safra Asset Management Corp grew its holdings in Vaxcyte by 649.4% in the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock valued at $46,000 after buying an additional 526 shares in the last quarter. Finally, Meeder Asset Management Inc. increased its position in Vaxcyte by 1,007.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock worth $80,000 after buying an additional 635 shares during the period. 96.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

PCVX has been the topic of several research reports. Mizuho upped their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research note on Tuesday, September 10th. Bank of America boosted their price target on Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research note on Wednesday, September 4th. Jefferies Financial Group lifted their price objective on Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Cantor Fitzgerald reissued an "overweight" rating on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, November 6th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte has a consensus rating of "Buy" and a consensus price target of $147.50.

Vaxcyte Stock Performance

Vaxcyte stock traded down $1.23 during trading hours on Tuesday, reaching $90.37. 869,495 shares of the company's stock were exchanged, compared to its average volume of 906,742. The firm's 50 day simple moving average is $105.60 and its 200 day simple moving average is $90.49. Vaxcyte, Inc. has a twelve month low of $52.74 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($1.10) by $0.27. During the same period in the prior year, the company earned ($0.91) earnings per share. As a group, analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Insider Buying and Selling

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the transaction, the chief financial officer now owns 90,383 shares in the company, valued at approximately $10,479,005.02. This represents a 8.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Grant Pickering sold 2,366 shares of the firm's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $103.89, for a total transaction of $245,803.74. Following the completion of the transaction, the chief executive officer now directly owns 137,398 shares in the company, valued at $14,274,278.22. This trade represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 87,464 shares of company stock valued at $9,797,926 over the last ninety days. 3.10% of the stock is owned by corporate insiders.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.